U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07784036) titled 'JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer' on Aug. 20.
Brief Summary: This is a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of JYP0035 Capsules in Combination With Fulvestrant in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Progressed on Prior Endocrine Therapy
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: JYP0035 plus Fulvestrant
JYP0035 capsules 100 mg administered orally twice daily (BID). Fulvestrant 500 mg...